Skye Bioscience Q1 FY26 net loss widens to $12.51 million; operating loss rises to $12.67 million

• Skye Bioscience posted a net loss of $12.51 million, widening from $11.1 million in prior-year quarter.
• Operating loss deepened to $12.67 million from $11.76 million, while no revenue was reported.
• Research and development expense rose 10% to $7.94 million, general and administrative expense increased 4% to $4.74 million.
• Cash, cash equivalents, and short-term investments fell to $17.11 million as of March 31, 2026, from $25.74 million at Dec. 31, 2025, with management expecting sufficient capital to operate through fourth-quarter 2026 excluding proposed Phase 2b and related manufacturing costs.
• Program update: CBeyond Phase 2a extension interim data showed 22.3% mean weight loss at 52 weeks in 7 completers on nimacimab with semaglutide, and an IV dosing expansion study started in March with topline data expected in fourth-quarter 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-033417), on May 11, 2026, and is solely responsible for the information contained therein.